Genetic differences in cytochrome P450 enzymes and antidepressant treatment response

Abstract

Aims:

Antidepressant response varies between patients, possibly due to differences in the rate cytochrome P450 enzymes metabolise antidepressants into inactive compounds. Drug metabolism rates are influenced by common variants in the genes encoding these enzymes. However, it remains unclear whether treatment outcomes can be predicted by either CYP450 genotype or antidepressant serum concentration.

Methods:

In GENDEP (a pharmacogenetic study of depressed individuals treated with either escitalopram or nortriptyline), serum concentrations of antidepressants and their primary metabolite were measured after eight weeks treatment and variants in CYP2D6 and CYP2C19 were genotyped.

Results:

Amongst patients taking escitalopram (n=223), the genotype CYP2C19 was significantly associated with escitalopram serum concentrations and desmethylescitalopram:escitalopram ratio. For those taking nortriptyline (n=161), the CYP2D6 genotype was significantly associated with nortriptyline and 10-hydroxynortriptyline serum concentrations and 10-hydroxynortriptyline:nortrip-tyline ratio. CYP450 genotypes conferring greater enzyme activity were linked to lower drug serum concentrations and higher metabolite:drug ratios. Nonetheless, no significant association was found between either CYP450 genotype or antidepressant serum concentration and treatment response.

Conclusions:

While there is a significant relationship between the CYP450 genotype and serum concentrations of escitalopram and nortriptyline, the genotypes are not predictive of differences in treatment response for either drug. Furthermore, differences in antidepressant serum concentrations are not associated with variability in treatment response.

Keywords

Antidepressant pharmacogenetics depression drug metabolism cytochrome P450 enzymes

Get full access to this article

View all access options for this article.

References

Asberg

Cronholm

Sjoqvist

. (1971) Relationship between plasma level and therapeutic effect of nortriptyline. Br Med J 3: 3313–34.

Brandl

Tiwari

Zhou

. (2013) Influence of CYP2D6 and CYP2C19 gene variants on antidepressant response in obsessive-compulsive disorder. Pharmacogenomics J, 12; in press.

Conney

Buening

Pantuck

. (1980) Regulation of human drug metabolism by dietary factors. Ciba Found Symp 76: 1471–67.

Couchman

(2012) Turbulent flow chromatography in bioanalysis: a review. Biomed Chromatogr 26: 8929–05.

Dahl

Bertilsson

Nordin

(1996) Steady-state plasma levels of nortriptyline and its 10-hydroxy metabolite: relationship to the CYP2D6 genotype. Psychopharmacology 123: 3153–19.

de Leon

Susce

Murray-Carmichael

(2006) The AmpliChip CYP450 genotyping test: Integrating a new clinical tool. Mol Diagn Ther 10: 1351–51.

FDA (2001) Guidance for industry. Bioanalytical method validation. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070107.pdf.

FDA (2011) FDA: Drug Interactions (CYP450 inhibitors and inducers). Available at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm#classInhibit.

Foglia

Pollock

Kirshner

. (1997) Plasma levels of citalopram enantiomers and metabolites in elderly patients. Psychopharmacol Bull 33: 1091–12.

10.

Freeman

Smith

Curtis

. (2003) DNA from buccal swabs recruited by mail: evaluation of storage effects on long-term stability and suitability for multiplex polymerase chain reaction genotyping. Behavior genetics 33: 677–2.

11.

Guengerich

(2007) Cytochrome P450 and chemical toxicology. Chemical Research in Toxicology 21: 708–3.

12.

Hall-Flavin

Winner

Allen

. (2012) Using a pharmacogenomic algorithm to guide the treatment of depression. Transl Psychiatry 2: e172.

13.

Hiemke

Baumann

Bergemann

. (2011) AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011. Pharmacopsychiatry 44: 1952–35.

14.

Hiemke

Hartter

(2000) Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther 85: 112–8.

15.

Huezo-Diaz

Perroud

Spencer

. (2012) CYP2C19 genotype predicts steady state escitalopram concentration in GENDEP. J Psychopharmacol 26: 3984–07.

16.

Ingelman-Sundberg

(2004) Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol Sci 25: 1932–00.

17.

Kirchheiner

Brosen

Dahl

. (2001) CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand 104: 1731–92.

18.

Kirchheiner

Nickchen

Bauer

. (2004) Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psych 9: 4424–73.

19.

Lamba

Lin

Schuetz

. (2002) Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 54: 12711–294.

20.

Linder

Keck

Jr. (1998) Standards of laboratory practice: antidepressant drug monitoring. National Academy of Clinical Biochemistry. Clin Chem 44: 10731–084.

21.

Mitchell

(2006) Depressed patients and treatment adherence. Lancet 367: 20412–043.

22.

Montgomery

Asberg

(1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134: 3823–89.

23.

Mrazek

Biernacka

O’Kane

. (2011) CYP2C19 variation and citalopram response. Pharmacogenet Genomics 21: 19–.

24.

Murphy

Jr. Pollock

Kirshner

. (2001) CYP2D6 genotyping with oligonucleotide microarrays and nortriptyline concentrations in geriatric depression. Neuropsychopharmacology 25: 7377–43.

25.

Nikisch

Mathe

Czernik

. (2004) Stereoselective metabolism of citalopram in plasma and cerebrospinal fluid of depressive patients: relationship with 5-HIAA in CSF and clinical response. J Clin Psychopharmacol 24: 2832–90.

26.

Olesen

Linnet

(1997) Hydroxylation and demethylation of the tricyclic antidepressant nortriptyline by cDNA-expressed human cytochrome P-450 isozymes. Drug Metab Dispos 25: 7407–44.

27.

Olesen

Linnet

(1999) Studies on the stereoselective metabolism of citalopram by human liver microsomes and cDNA-expressed cytochrome P450 enzymes. Pharmacology 59: 2983–09.

28.

Ostad Haji

Tadic

Wagner

. (2011) Association between citalopram serum levels and clinical improvement of patients with major depression. J Clin Psychopharmacol 31: 2812–86.

29.

Perry

Zeilmann

Arndt

(1994) Tricyclic antidepressant concentrations in plasma: an estimate of their sensitivity and specificity as a predictor of response. J Clin Psychopharmacol 14: 2302–40.

30.

Peters

Slager

Kraft

. (2008) Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR D sample. PloS one 3: e1872.

31.

Rebsamen

Desmeules

Daali

. (2009) The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction. Pharmacogenomics J 9: 344–1.

32.

Reis

Aamo

Spigset

. (2009) Serum concentrations of antidepressant drugs in a naturalistic setting: compilation based on a large therapeutic drug monitoring database. Ther Drug Monit 31: 425–6.

33.

Rudberg

Mohebi

Hermann

. (2008) Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients. Clin Pharmacol Ther 83: 3223–27.

34.

Sim

Risinger

Dahl

. (2006) A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clini Pharmacol Ther 79: 1031–13.

35.

StataCorp. (2009) Stata Statistical Software: Release 11. College Station, TX: StataCorp LP.

36.

Tansey

Guipponi

Perroud

. (2012) Genetic predictors of response to serotonergic and noradrenergic antidepressants in major depressive disorder: a genome-wide analysis of individual-level data and a meta-analysis. PLoS Med 9: e1001326.

37.

Tsai

Lin

Hsiao

. (2010) Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response. Pharmacogenomics 11: 5375–46.

38.

Uher

Huezo-Diaz

Perroud

. (2009) Genetic predictors of response to antidepressants in the GENDEP project. Pharmacogenomics J 9: 2252–33.

39.

Uher

Perroud

. (2010) Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. Am J Psychiatry 167: 5555–64.

40.

Uher

Tansey

Malki

. (2012) Biomarkers predicting treatment outcome in depression: what is clinically significant? Pharmacogenomics 13: 2332–40.

41.

van der Weide

Steijns

(1999) Cytochrome P450 enzyme system: genetic polymorphisms and impact on clinical pharmacology. Ann Clin Biochem 36 (Pt 6): 7227–29.

42.

Vandel

Sandoz

. (1978) Clinical response and plasma concentration of amitriptyline and its metabolite nortriptyline. Eur J Clin Pharmacol 14: 1851–90.

43.

Wing

Sartorius

Üstün

(1998) Diagnosis and clinical measurement in psychiatry: a reference manual for SCAN. Cambridge University Press.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.20 MB